RET fusion gene: Translation to personalized lung cancer therapy

Cancer Science

Volumn 104, Issue 11, 2013, Pages 1396-1400

  Kohno, Takashi ^a,b   Tsuta, Koji ^c   Tsuchihara, Katsuya ^a   Nakaoku, Takashi ^b   Yoh, Kiyotaka ^d   Goto, Koichi ^d  

^a NATIONAL CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOA KINASE; CABOZANTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EXELIXIS; LENVATINIB; PONATINIB; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB;

ALK GENE; CANCER PATIENT; CCDC6 RET FUSION GENE; EGFR GENE; FUSION GENE; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIF5B RET FUSION GENE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; NCOA4 RET FUSION GENE; ONCOGENE K RAS; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; TREATMENT RESPONSE; TRIM33 RET FUSION GENE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; PREVALENCE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET;

EID: 84886787498     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12275     Document Type: Review

References (31)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010 (Sep-Oct); 60: 277-300.
2. Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013 (Mar); 31: 1097-104.
3. Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat Med 2012 (Mar); 18: 349-51.
4. Imielinski M. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012; 150: 1107-20.
5. Maemondo M, Inoue A, Kobayashi K et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 (Jun 24); 362: 2380-8.
6. Oizumi S, Kobayashi K, Inoue A et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 2012; 17: 863-70.
7. Shaw AT, Engelman JA. ALK in lung cancer: past, present, and future. J Clin Oncol 2013 (Mar 10); 31: 1105-11.
8. Mano H. ALKoma: a cancer subtype with a shared target. Cancer Discov 2012 (Jun); 2: 495-502.
9. Sakamoto H, Tsukaguchi T, Hiroshima S et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011 (May 17); 19: 679-90.
10. Takeuchi K, Soda M, Togashi Y et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med 2012 (Mar); 18: 378-81.
11. Lipson D, Capelletti M, Yelensky R et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012 (Mar); 18: 382-4.
12. Kohno T, Ichikawa H, Totoki Y et al. KIF5B-RET fusions in lung adenocarcinoma. Nat Med 2012 (Mar); 18: 375-7.
13. Ju YS, Lee WC, Shin JY et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res 2012 (Mar); 22: 436-45.
14. Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Multikinase inhibitors: a new option for the treatment of thyroid cancer. Nat Rev Endocrinol 2011 (Oct); 7: 617-24.
15. Borrello MG, Ardini E, Locati LD, Greco A, Licitra L, Pierotti MA. RET inhibition: implications in cancer therapy. Expert Opin Ther Targets 2013 (Apr); 17: 403-19.
16. Drilon A, Wang L, Hasanovic A et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov 2013 (Jun); 3: 630-5.
17. Suzuki M, Makinoshima H, Matsumoto S et al. Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo. Cancer Sci 2013 (Apr 11); 104: 896-903.
18. Matsubara D, Kanai Y, Ishikawa S et al. Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad. J Thorac Oncol 2012 (Dec); 7: 1872-6.
19. Cai W, Su C, Li X et al. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer. Cancer 2013 (Apr 15); 119: 1486-94.
20. Wang R, Hu H, Pan Y et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 2012 (Dec 10); 30: 4352-9.
21. Suehara Y, Arcila M, Wang L et al. Identification of KIF5B-RET and GOPC-ROS1 fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. Clin Cancer Res 2012 (Dec 15); 18: 6599-608.
22. Kim SC, Jung Y, Park J et al. A high-dimensional, deep-sequencing study of lung adenocarcinoma in female never-smokers. PLoS ONE 2013; 8: e55596.
23. Yokota K, Sasaki H, Okuda K et al. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung. Oncol Rep 2012 (Oct); 28: 1187-92.
24. Li F, Feng Y, Fang R et al. Identification of RET gene fusion by exon array analyses in "pan-negative" lung cancer from never smokers. Cell Res 2012 (May); 22: 928-31.
25. Chu CT, Sada YH, Kim ES. Vandetanib for the treatment of lung cancer. Expert Opin Investig Drugs 2012 (Aug); 21: 1211-21.
26. Gautschi O, Zander T, Keller FA et al. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013 (May); 8(5): e43-4.
27. Mazieres J, Peters S, Lepage B et al. Lung cancer that Harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013 (Jun 1); 31: 1997-2003.
28. Gautschi O, Pauli C, Strobel K et al. A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol 2012 (Oct); 7(10): e23-4.
29. Awad MM, Katayama R, McTigue M et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med 2013 (Jun 1); 368: 2395-401.
30. Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol 2013 (May 20); 31: 1904-11.
31. Yoshida A, Kohno T, Tsuta K et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013 (Apr); 37: 554-62.